300
Participants
Start Date
April 8, 2024
Primary Completion Date
January 13, 2025
Study Completion Date
January 13, 2025
Liraglutide
Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
National Taiwan University Hospital, Taipei
Genesis Clinic, Taipei
Taipei Medical University Hospital, Taipei
HsinChu MacKay Memorial Hospital, Hsinchu
HsinChu Municipal MacKay Children's Hospital, Hsinchu
Ton-Yen General Hospital, Hsinchu County
Chang Gung Memorial Hospital Linkou, Taoyuan
China Medical University Hospital, Taichung
Kuang Tien General Hospital, Taichung
Tungs Taichung MetroHarbor Hospital, Taichung
Changhua Christian Hospital, Changhua
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
TZ Clinic, Pingtung County
National Taiwan University Hospital, Taipei
Lead Sponsor
Novo Nordisk A/S
INDUSTRY